September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Predictive factors for non-response to intravitreal aflibercept treatment in neovascular age-related macular degeneration
Author Affiliations & Notes
  • Norihiro Nagai
    Laboratory of Retinal Cell Biology, Keio University, School of Medicine, Tokyo, Japan
    Ophthalmology, Keio University, School of Medicine, Tokyo, Japan
  • Misa Suzuki
    Laboratory of Retinal Cell Biology, Keio University, School of Medicine, Tokyo, Japan
    Ophthalmology, Keio University, School of Medicine, Tokyo, Japan
  • Atsuro Uchida
    Ophthalmology, Keio University, School of Medicine, Tokyo, Japan
  • Toshihide Kurihara
    Ophthalmology, Keio University, School of Medicine, Tokyo, Japan
  • Mamoru Kamoshita
    Laboratory of Retinal Cell Biology, Keio University, School of Medicine, Tokyo, Japan
    Ophthalmology, Keio University, School of Medicine, Tokyo, Japan
  • Sakiko Minami
    Ophthalmology, Keio University, School of Medicine, Tokyo, Japan
  • Hajime Shinoda
    Ophthalmology, Keio University, School of Medicine, Tokyo, Japan
  • Kazuo Tsubota
    Ophthalmology, Keio University, School of Medicine, Tokyo, Japan
  • Yoko Ozawa
    Laboratory of Retinal Cell Biology, Keio University, School of Medicine, Tokyo, Japan
    Ophthalmology, Keio University, School of Medicine, Tokyo, Japan
  • Footnotes
    Commercial Relationships   Norihiro Nagai, None; Misa Suzuki, None; Atsuro Uchida, None; Toshihide Kurihara, None; Mamoru Kamoshita, None; Sakiko Minami, None; Hajime Shinoda, None; Kazuo Tsubota, None; Yoko Ozawa, None
  • Footnotes
    Support  n/a
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 3689. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Norihiro Nagai, Misa Suzuki, Atsuro Uchida, Toshihide Kurihara, Mamoru Kamoshita, Sakiko Minami, Hajime Shinoda, Kazuo Tsubota, Yoko Ozawa; Predictive factors for non-response to intravitreal aflibercept treatment in neovascular age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 2016;57(12):3689.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To study the baseline characteristics and response to intravitreal aflibercept (IVA) monotherapy of neovascular age-related macular degeneration (AMD).

Methods : We reviewed the clinical records of 133 eyes in 133 AMD patients who received monthly IVA for 3 months and thereafter pro re nata (PRN) injections for 9 months. Sixty-two patients were initially treatment naïve (naïve group), and 71 patients had been received other treatments before IVA treatment (switched group). Patients with increased exudative fundus findings or central retinal thickness (CRT) of more than 100 μm at month 12, or no decrease of CRT during treatment were considered to be non-responders as judged by fundus findings. Patients whose best corrected visual acuity (BCVA) worsened at month 12 were considered to be non-responders as judged by BCVA. Non-responders’ baseline characteristics were analyzed using logistic regression models. In the multivariable analysis, potential risk factors for non-responders were adjusted for age, CRT, and greatest linear dimension at baseline. The study followed the tenets of the Declaration of Helsinki and was approved by the ethics committee of Keio University School of Medicine (2010002) and registered as UMIN000007649.

Results : IVA treatment significantly decreased CRT both in naïve and switched group. Although BCVA of naïve group was significantly improved, that of switched group was not changed. Non-responders as judged by fundus findings was 12.9% and 5.6%, and those by BCVA was 9.7% and 15.5%, in naïve and switched groups, respectively. Serous pigment epithelial detachment at baseline was associated with non-response as judged by fundus findings in naïve group (Odds ratio (OR) 23.0, 95%CI 2.69-192) and those by BCVA in the switched group (OR 5.14, 95%CI 1.16-22.8). Female gender was associated with non-response as judged by BCVA in the naïve group (OR 6.88, 95% CI 1.07 to 44.1).

Conclusions : Although most AMD patients responded to IVA, there were non-responders whose baseline characteristics may be informative for managing their treatment.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×